Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized…

By M. J. van den Bent, A. Carpentier, A. Brandes, M. Sanson, M. Taphoorn, H. Bernsen, M. Frénay, C. Tijssen, W. Grisold, L. Sipos and 7 more. Journal of Clinical Oncology, 2006

707 citations recorded by the source corpus.

Subfields: Genetics, Neurology

View Paper: https://www.semanticscholar.org/paper/7e7613dcc408b7391ccb248001b93a37f6cf51b5

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. H. Ohgaki
2. P. Kleihues
3. R. Jenkins
4. Guido Reifenberger
5. Michael Weller
6. McKinsey L. Goodenberger

Citations in the corpus

• The 2007 WHO classification of tumours of the central nervous system (2007, result): “Two large studies of malignant gliomas suggest that necrosis is associated with signiWcantly worse prognosis in anaplastic gliomas with both oligodendroglial and astrocytic components [36, 50]: patients whose tumours showed necrosis had a substantially shorter median overall survival compared to pat”
• EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. (2014, background): “Extent of resection is a prognostic factor in these tumors, too.(7,15) Although RT (54-60 Gy, 1.”
• Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. (2009, background): “Allelic losses on chromosome arms 1p and 19q are associated with a favorable prognosis in patients with oligodendroglial and oligoastrocytic anaplastic gliomas treated with radiotherapy or radiotherapy plus chemotherapy.(6-9) MGMT promoter hypermethylation is associated with prolonged progression-fr”
• Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. (2013, background): “Early results from RTOG 9402 and EORTC 26951 showed that progression-free survival (PFS) was prolonged by adding PCV to RT and that patients with codeleted tumors lived longer.(19,20) In RTOG 9402, the progression-free survival benefit was only seen in the codeleted subset.”
• The 2007 WHO Classification of Tumours of the Central Nervous System (2007, background): “Two large studies of malignant gliomas suggest that necrosis is associated with signiWcantly worse prognosis in anaplastic gliomas with both oligodendroglial and astrocytic components [36, 50 ]: patients whose tumours showed necrosis had a substantially shorter median overall survival compared to p”
• A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. (2006, background): “Similar prognostic but not predictive conclusions were drawn by the simultaneous EORTC trial of PCV and radiation in patients with anaplastic oligodendrogliomas (11).”